Guidelines for the Use of Intravenous Immune Globulin for Hematologic and Neurologic Conditions

Transfusion Medicine Reviews

Volumn 21, Issue SUPPL. 1, 2007, Pages S1-

  Hume, Heather A ^a,b   Anderson, David R ^a,b  

^a CANADIAN BLOOD SERVICES   (Canada)

^b The National Advisory Committee on Blood and Blood Products   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

BLOOD BANK; BLOOD TRANSFUSION; BUDGET; CANADA; DISEASE SEVERITY; DRUG COST; DRUG INDICATION; DRUG SAFETY; DRUG USE; EDITORIAL; FUNDING; HEALTH CARE FACILITY; HEMATOLOGIC DISEASE; HEMOLYSIS; HUMAN; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; THROMBOEMBOLISM;

EID: 33947707954     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2007.01.003     Document Type: Editorial

References (3)

1. www.blood.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/resources/Fracti onation/$file/1_00-05_en.pdf Accessed Jan 24, 2007
2. Pierce L.R., and Jain N. Risks associated with the use of intravenous immunoglobulin. Trans Med Rev 17 (2003) 241-251
3. Hamrock D.J. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 6 (2006) 535-542